Superior Performance, Reliable Results.

Find It detects common, clinically relevant genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 337 hotspots and 26 exons in 38 known cancer-associated genes simultaneously.

Find It detects indications for non-small cell lung cancer, melanoma, colorectal cancer, GIST, basal cell, breast cancer, endometrial, and other solid tumor cancers.

GenePosition
AKT1E17
ALKT1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275, Y1278
ARL702, V716, S741, W742, Q784, H875, F877, T878, M896
BRAF Q201, G464, G466, F468, G469, Y472, D594, F595, G596, L597, V600, K601, part of Exon15 (V600-M620), G606
CCNEAmplification
CTNNB1D32, S33, G34, I35, H36, S37, T41, S45
DDR2L239, I638, S768
DICER1D1705-D1709, G1809, D1810-E1813
EGFRR108, A289, S492, P596, G598, Exon18, Exon19, Exon20, Exon21, & Amplification
ERBB2G309, S310, K753, L755, I767, D769, Exon20, & Amplification
ESR1K303, E380, S463, V534, P535, L536, Y537, D538
FGFR1N546, K656, & Amplification
FGFR2S252, P253, W290, A315, S372, Y375, C382, N549, K659, E731, E777, & Amplification
FGFR3R248, S249, G370, S371, Y373, G380, A391, K650
FOXL2C134
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITS476, Y553, W557,, V559, V560, L576, K642, V654, T670, D816, D820, N822, Y823, A829, Exon9, Exon11, Exon13, & Amplification
KRASK5, A11, G12, G13, L19, Q22, A59, G60, Q61, K117, A146, & Amplification
MAP2K1(MEK1)F53, Q56, K57, K59, V60, D67, I103, I111, C121, N122, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119, H123, G132
METT1010, V1112, H1112, G1181, L1213, D1246, Y1248, Y1253, Exon13, Exon14, Exon14 (-50 to+25), Exon18, Amplification
NRASG12, G13, A59, G60, Q61, K117, A146
NTRK1F589, G595, G667
NTRK3G623, G696
PDGFRAR560-E571, P577, N659, L839-Y849, D842
PIK3CAR88, C90, R93, P104, G106, N107, R108, K111, R115, N345, R357, G364, E365, Exon6 [start to P377], C420, E453, P539, E542, E545, Q546, D549, E970, E978, M1043, N1044, A1046, H1047, G1049 + Amplification
POLEExons 9-14 (P286R, M295R, S297F, F367S, D368Y, V411L, L424I, M444K, A456P, S459F)
PTCH1W844, G1093
PTENA126, G129, R130, R173, R233, K254-K267
RETG533, K603, C609, C611, C618, C620, C630, D631, C634, G691, E768, L790, Y791, V804, Y806, A883, R886, S904, M918, A919, Exon10, Exon 13, Exon15
ROS1S1986, G2032, L2026
STK11Q37, P281
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9
MSI21 Loci
Basal Cell Carcinoma
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
PTCH1 oncogenic mutationsYesYesIANo
Breast Cancer
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
AKT1 E17KNoNoIBNo
ERBB2 amplificationYesYesIANo
ERBB2 oncogenic mutationsNoNoIBNo
ESR1 oncogenic mutationsNoNoIBNo
FGFR1 amplificationNoNoIICNo
PIK3CA oncogenic mutationsYesYesIANo
MSI-HYesYesIANo
Colorectal Cancer
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
BRAF V600EYesYesIANo
ERBB2 AmplificationYesYesIA/IBYes
KRAS wild typeYesYesIANo
KRAS and NRAS wild-typeYesYesIANo
KRAS and NRAS oncogenic mutationsYesYesIAYes
MSIYesYesIANo
Esophageal
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
ERBB2 AmplificationYesYesIANo
Gastric
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
ERBB2 AmplificationYesYesIANo
MSIYesYesIANo
GIST
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
KIT oncogenic mutationsYesYesIA/IIDNo
KIT A829, D816, D820, N822, T670, V654, Y823YesYesIIDYes
KIT V654YesYesIIDYes
PDGFRA oncogenic mutationsYesYesIANo
PDGFRA D842YesYesIAYes
NSCLC
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
ALK oncogenic mutationsYesNoIA/IIDYes
BRAF V600EYesYesIANo
EGFR G719 (exon 18), exon 19 deletions, S768I (exon 20), L858R, L861Q (exon21)YesYesIANo
EGFR exon 19 deletions, L858R (exon 21)YesYesIANo
EGFR exon 20 insertion, T790M (exon 20)YesYesIAYes
EGFR T790M (exon 20), L858R (exon 21)YesYesIANo
EGFR C797, L718, L792, G796YesYesIIDYes
EGFR exon 20 insertionYesYesIANo
EGFR exon 18 indelNoYesIBNo
EGFR exon 19 insertionNoYesIBNo
EGFR exon 19 & 20 insertion, L747NoYesIIDNo
ERBB2 oncogenic mutationsYesYesIANo
KRAS G12CYesYesIANo
MAP2K1 oncogenic mutationsNoNoIBNo
MET exon 14 skippingYesYesIANo
MET amplificationYesYesIA/IIDYes
Melanoma
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
BRAF V600YesYesIANo
BRAF V600EYesYesIANo
BRAF V600KYesYesIANo
BRAF L597, V601NoYesIBNo
KIT oncogenic mutationsYesYesIANo
MAP2K1 oncogenic mutationsNoNoIBNo
NRAS oncogenic mutationsNoYesIB/IIDNo
Urothelial Cancer
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
FGFR3 R248C, S249C, G370C, Y373CYesYesIANo
FGFR3 S371C, G380R, K650NoYesIBNo
HRAS oncogenic mutuationsNoNoIBNo
All Solid Tumors
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
BRAF G464, G469, L597, K601NoNoIIDNo
FGFR1, FGFR2, FGFR3 oncogenic mutationsNoNoIIDNo
KRAS oncogenic mutationsNoNoIIDNo
Microsatellite Instability-High (MSI-H)YesYesIANo
NTRK1 and NTRK3 mutationsYesNoIAYes
NTRK1 G595RYesNoIIDYes
PTEN oncogenic mutationsNoNoIIDNo
Ovarian
Biomarkers detected by Find It®Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
AKT1 E17KNoNoIBNo
CCNE1 AmplificationNoNoIIDYes
MAP2K1 oncogenic mutationsNoNoIBNo
Genes38
Hotspots337
Exons26
Turnaround Time3-5 days
Mutation typesSNVs, deletions and insertions(up to 24bp), CNVs and MSI
Sample TypeScrolls/curls & unstained slides
Sample RequirementSample requirements are the same if you are ordering just Find It, just Fusions, or both assays. Please include one H&E slide or a digital image (to test@canexiahealth.com) from the same FFPE block, including the circled tumour area. Please complete specimen details on the TRF including the % tumour content.

Benefits

Key Content

Find It targets genomic content associated with approved therapies, treatment resistance, disease prognosis, and clinical trials.

Rapid Turnaround Time

A simple laboratory workflow that provides rapid, reliable, results.

Comprehensive Reports

Automated reporting from the Canexia Health Insights Platform provides up-to-date information on interpretations, current treatment options, and available clinical trials.

Cost-Effective

Targeted amplicon-based technology provides an economical alternative to single-gene testing or hybrid capture NGS assays.

Conserve Biopsy Tissue

Find It and Fusions single sample panels allows for simultaneous hotspot testing, reducing the amount of biopsy tissue required.

High Quality

All Canexia Health assays and software are developed in our CLIA, CAP, CDPH and DAP accredited laboratory.

View Other Solutions

Plasma (Follow It®)

Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.

Learn About Follow It

Tissue

Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.

Learn About Tissue Assays

Canexia Health Insights Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Your Labs, Our Technology

From mutation identification to auto-generated reports, Canexia Health’s proprietary platform allows you to perform mutation assay for cancer right from your laboratory.

Learn More

Make Faster Treatment Decisions

Canexia’s Clinical Services can support your local lab bring precision oncology testing in-house.

Get Started Today